Navigation Links
Boston Scientific Begins Clinical Trial Enrollment in China for PROMUS Element™ Everolimus-Eluting Stent
Date:1/26/2011

ty while permitting thinner struts compared to prior-generation stents(1).

"PLATINUM China represents the Company's first major coronary drug-eluting stent trial with enrollment exclusive to China," said Keith D. Dawkins, M.D., Senior Vice President and Chief Medical Officer, Cardiology, Rhythm and Vascular Group for Boston Scientific.  "The Element Stent series has been well received by physicians in CE Mark countries, and we look forward to bringing this advanced coronary stenting technology to Chinese physicians and their patients."

The Company received CE Mark approval for the PROMUS Element Everolimus-Eluting Stent System in October 2009 and for the TAXUS® Element™ Paclitaxel-Eluting Stent System in May 2010.  Both Element systems incorporate the same platinum chromium alloy, innovative stent design and advanced catheter delivery system.

"We are excited to begin evaluating the PROMUS Element Stent in China," said Hank Kucheman, Executive Vice President and Group President, Cardiology, Rhythm and Vascular for Boston Scientific.  "The advanced platinum chromium alloy and new balloon catheter offered in the Element Stent System represent significant improvements over prior-generation stents.  We are confident that the next-generation Element platform will further extend our global drug-eluting stent leadership."

In the U.S., the Company expects Food and Drug Administration approval for the TAXUS Element Stent System(2) in mid 2011 and for the PROMUS Element Stent System in mid 2012.  In Japan, the Company expects approval for the TAXUS Element Stent System in late 2011 or early 2012 and for the PROMUS Element Stent System in mid 2012.

In the U.S., the PROMUS Element Stent System and the TAXUS Element Stent System are investigational devices and are limited by applicable law to investigational use only and are not available for sale.  

(1) Based on bench testing.  Data on file
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Boston Scientific Completes Enrollment in EVOLVE Clinical Trial to Evaluate SYNERGY™ Drug-Eluting Coronary Stent
2. Boston Scientific Announces Agreement With Fukuda Denshi for Distribution of Cardiac Rhythm Management Products in Japan
3. Boston Scientific to Webcast Conference Call Discussing Fourth Quarter and Full Year 2010 Financial Results
4. Boston Scientific to Acquire Atritech
5. Boston Scientific Completes Enrollment in Clinical Trial Evaluating Next-Generation Nitinol Stent to Treat Iliac Artery Disease
6. Statement of Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, Boston Scientific on JAMA Article
7. Boston Scientific Completes Acquisition of Sadra Medical
8. Stryker Completes Acquisition of the Neurovascular Division of Boston Scientific
9. Boston Scientific Completes Sale of Neurovascular Business
10. Boston Scientific to Present at 29th Annual J.P. Morgan Healthcare Conference
11. Boston Scientific Announces Election of Dr. Kristina M. Johnson to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Mass. , Sept. 19, 2014  Pressure ... today announced it has received and approved all ... HT48 instruments and has begun to manufacture the ... first instrument will be ready for shipment by ... built and released at a rate of about ...
(Date:9/19/2014)... 19, 2014  Over 200 runners participated in the ... the Radiation Oncology Institute (ROI), hosted by Radiation Business ... Park in San Francisco.  "Donations are ... of Radiation Business Solutions, "but at this point, ... $70,000 for the ROI this year. This surpasses last ...
(Date:9/19/2014)... PHILADELPHIA , Sept. 19, 2014  PCI ... Services International (Biotec).  Biotec is a leading provider ... Services headquartered in Bridgend, Wales ... .  The addition significantly expands PCI,s presence in ... medicinal products by adding packaging, storage and distribution ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6
... ,Forest Laboratories, Inc. (NYSE: FRX ) and ... a phase II clinical trial of,cariprazine (RGH-188), an ... bipolar I disorder. For the primary endpoint,the Young ... patients with,acute manic episodes treated with cariprazine experienced ...
... Phase II Data Continue to Highlight Potential of NeoVista,s ... Epiretinal ... 18-month data from the company,s Phase II feasibility study,examining its novel ... (AMD) at the 41st Scientific Meeting of,the Retina Society. The long-term ...
Cached Medicine Technology:Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder 2Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder 3Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder 4Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder 5NeoVista Unveils 18-month Data on Novel Wet AMD Therapy at Retina Society Meeting 2NeoVista Unveils 18-month Data on Novel Wet AMD Therapy at Retina Society Meeting 3NeoVista Unveils 18-month Data on Novel Wet AMD Therapy at Retina Society Meeting 4
(Date:9/20/2014)... 2014 Ticket Down is a ... for her 2015 “Honeymoon Tour.” This well-known ticket exchange ... savings. , In early 2015, fans will have a chance ... across North America. Twenty-one-year-old Ariana Grande will hit the road ... her to 25 cities across the United States and Canada. ...
(Date:9/20/2014)... New York, New York (PRWEB) September 20, 2014 ... of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in ... notes that yet another insurer has announced plans ... a statement posted on its website last month, ... such procedures effective November 1, 2014. The insurer ...
(Date:9/20/2014)... Recently, Best Cheap Hosting USA (best-cheap-hosting-usa.com), ... new website. The new site provides the latest ... for customers. Here, people can find a lot ... Also, it has recommended some excellent web hosting ... the great web hosting suppliers, InMotion ( http://www.best-cheap-hosting-usa.com/go/InMotion/ ...
(Date:9/20/2014)... dentists have advised their patients against drinking coffee and wine. ... that advice and changing his stance after considering two recent ... oral health. “There’s good news and great news,” says Dr. ... protecting against gum disease, and red wine can help fight ... the September 2014 issue of Boston University School of ...
(Date:9/20/2014)... September 20, 2014 Recently, UWDress.com, an ... and women’s special occasion outfits, has launched a special ... company’s prom outfits are popular among worldwide clients. Now, ... wholesale prom dresses on its website. , ... customers from around the world. Great custom made items ...
Breaking Medicine News(10 mins):Health News:Ariana Grande Tickets in New York, Philadelphia, Orlando, Fairfax, Worcester, Toronto, Uncasville, Detroit, Miami, Pittsburgh, Cleveland, and Atlanta On Sale Today 2Health News:Ariana Grande Tickets in New York, Philadelphia, Orlando, Fairfax, Worcester, Toronto, Uncasville, Detroit, Miami, Pittsburgh, Cleveland, and Atlanta On Sale Today 3Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 3Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 2Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 3Health News:Discounted 2014 Prom Dresses Provided By Innovative Company UWDress.com 2
... 12 Having funded $2 million,total to support 27 ... year of its Rapid Response Innovation Awards,(RRIA) initiative, The ... $2 million to a second round of funding in ... good ideas without delay.,Under this program the Foundation accepts ...
... 12, 2007) A new study confirms that chronic ... cardiovascular events in diabetic patients with damage to the ... anti-diabetic drug pioglitazone may help to lower this risk, ... Nephrology. , "The data confirm that chronic kidney disease ...
... Government Officials Will Explain Regulatory Plans for Cutting-Edge,Technology at ... Dec. 12 Nanotechnology was,incorporated into more than $50 ... By 2014, the market will grow to $2.6 trillion.,By ... will be,sold -- up from more than $3 billion ...
... Dermatologist Doing His Part to Warn Consumers, OMAHA, ... has been in the news for the past several ... Fig, the,parent company for up to 18 facilities around ... procedure, has closed its stores and is,considering declaring bankruptcy. ...
... Mattel Children,s Hospital UCLA,interacting with more than 100 Children ... ... NEW YORK, Dec. 12 Vapps, Inc., the ... today,will premiere their inaugural "Vapps, Holiday Storybook" event, featuring,multi-platinum ...
... depressive disorder (MDD) is the most common major mental ... 75% of people who recover from an episode of ... majority having multiple recurrences. MDD is the leading ... functional impairment, morbidity, and mortality. Few studies have assessed ...
Cached Medicine News:Health News:Michael J. Fox Foundation Launches Rapid Response Innovation Awards 2008 Following Strong Inaugural Year Response 2Health News:Pioglitazone lowers cardiovascular risk in diabetic patients with kidney disease 2Health News:Food and Drug Law Institute, Project on Emerging Nanotechnologies Co-Sponsor Major Conference on Nanotechnology Law, Regulation and Policy 2Health News:Food and Drug Law Institute, Project on Emerging Nanotechnologies Co-Sponsor Major Conference on Nanotechnology Law, Regulation and Policy 3Health News:Food and Drug Law Institute, Project on Emerging Nanotechnologies Co-Sponsor Major Conference on Nanotechnology Law, Regulation and Policy 4Health News:Will Lipodissolve Continue to Remain Popular? 2Health News:Ashlee Simpson to Read Holiday Stories to Children in Hospitals Throughout the Country Premiering 'Vapps' Holiday Storybook' Event 2Health News:Venlafaxine extended-release effective for patients with major depression 2
Double-ended. Designated most popular model or size....
Double-ended. Sharp and blunt 6.5 mm tips. Designated most popular model or size....
2 mm tip....
Octagonal handle. 3 mm wide....
Medicine Products: